Despite the proven clinical efficacy of phosphodiesterase inhibitors in the treatment of erectile dysfunction (ED), some patients do not respond to the medication. By means of nailfold capillary microscopy in patients with concomitant coronary artery disease (CAD) and ED, it was evaluated whether the extent of microvascular dysregulation predicts the responsiveness to tadalafil (TAD) in terms of erectile function. The ED of each patient was assessed by the International Index of Erectile Function (IIEF). Patients presenting both, documented CAD and ED, showed a significantly reduced capillary red blood cell velocity (v RBC ) at rest and after 3 min of ischemia compared with age-matched controls. At 2 h after intake of 20 mg of TAD, a significant increase of v RBC at rest as well as during postischemic hyperemia was found. Patients who reported no improvement of their ED after the use of TAD demonstrated no changes in the duration of postischemic (DpH) hyperemia, or even a reduction of the DpH. The majority of the patients, who reported at least one successful sexual intercourse due to TAD, had a prolongation of DpH. We conclude that assessment of microvascular regulation by nailfold capillary microscopy can predict the probability of a treatment failure with phosphodiesterase inhibitors in patients with ED. Moreover, as endothelial dysfunction is the common underlying pathophysiological process of ED and cardiovascular diseases, the test may help to identify patients at risk for the development of atherosclerosis and following cardiovascular events.
Introduction
A growing body of scientific reports offers convincing evidence that age-related erectile dysfunction (ED) may be an early clinical manifestation of a generalized vascular disease. 1 Cardiovascular risk factors such as hypertension, hypercholesterolemia, diabetes mellitus or cigarette smoking are known causes of a disturbed homeostatic equilibrium of vascular endothelial cells, referred to as endothelial dysfunction, which plays a pivotal role in the pathophysiology of vasculogenic ED. 2, 3 Among others, endothelial dysfunction is associated with an impaired release and activity of nitric oxide (NO). NO is a vasodilatory neurotransmitter required for the activation of guanylyl cyclase, which increases the concentration of the second messenger, cyclic guanosine monophosphate (cGMP). Elevated levels of cGMP lead to a drop of intracellular calcium concentrations which results in relaxation of arterial smooth muscles. 4 Therefore, the impairment of the NO pathway is the critical determinant for the decrease in vasodilatory capacity in patients with endothelial dysfunction. 5 The penis is a highly vascularized part of the body and the concentration of endothelial cells in it is relatively many times than that of other organs. 6 Firmness and maintenance of the penile erection is a result of a series of events, from psychosomatic stimulation to vascular response, in which the NO pathway is critically involved. Disruption of this pathway may lead to ED. 1, 2, 6, 7 Moreover, the vasodilatory effect of the NO system is counter-regulated by the cleavage of cGMP by phosphodiesterase type 5 (PDE5). In early stages of atherosclerosis without clinical symptoms, high concentrations of PDE-5, in particular of the subtype PDE5 A2, and a reduced release of nitric oxide (NO) can be found in both, the smooth muscle cells of the cavernous body 8 and of coronary arteries. 9 On the one hand, ED is associated with endothelial dysfunction and resultant impairment of macrovascular vasoregulation in patients with nonouvert 10, 11 or early coronary artery disease (CAD).
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On the other hand, in patients with cardiovascular risk factors [13] [14] [15] or known CAD, 16 ,17 a microcirculatory disturbance can be found. The characteristic findings in patients with advanced cardiovascular diseases are a diminished amplitude and a shortened duration of the postischemic hyperemia. 15, 17 Owing to the small diameter of the cavernosal arteries of approximately 100 mm, 18 which belong to the microvascular bed, it can be assumed that ED belongs to the group of microvascular disorders. To our knowledge, a previous study of our group was the first to demonstrate a microvascular dysregulation in patients with ED by means of nailfold capillary microscopy. 19 Phosphodiesterase type 5 inhibitors (PDE5i) have been successfully introduced in first-line oral therapy for ED. 20, 21 Nevertheless, in spite of the proven clinical efficacy, non-response to treatment with PDE5i seems to be a common problem in daily practice. 22 Major causes of individual treatment failure are non-vascular origin of ED, for example in patients with psychiatric or neurologic disorders, 22 or inappropriate counseling or dosing by the prescribing physician. 23, 24 At present, patients are defined as non-responders after four unsuccessful attempts using the highest tolerated dose of a PDE5i. 24 Hence, a simple non-invasive test to separate true non-responders from the group of patients in whom a PDE5i should basically be effective could be helpful to shorten the time of therapeutic attempts. In the setting of the aforementioned interrelations between vascular disorders and ED, and our own experience, 19 we hypothesized that the finding of a microcirculatory disturbance may predict the responsiveness to PDE5i of a patient with ED. Thus, as a proof of concept, we studied patients with concomitant CAD and ED in respect of the effect of tadalafil (TAD) on both, erectile function and cutaneous capillary perfusion.
Methods

Study design
The study data were prospectively collected as a registry of consecutive patients within a framework of quality control. All participants were recruited from the ED consult hour of the Cardiology Division of the Hoyerswerda Hospital, Germany, and signed an informed consent. Male patients, 18 years or older, with an angiographically proven CAD with at least one coronary artery branch of first or secondary order with a degree of stenosis of 50% or higher 25 and known ED were included into the registry. Female patients or patients with a proven macroangiopathy of the upper extremities were excluded from the study. The trial was planned and conducted in compliance with the Declaration of Helsinki/Somerset West.
The status of the arm arteries was assessed by measuring the blood pressures in the brachial, radial and ulnar artery. The measurement of the wrist blood pressures was performed at rest as well as after a workload using a training device. A macroangiopathy of the arteries of the arm was assumed when the blood pressure in the wrist arteries was lower than in the brachial artery even in asymptomatic patients. The forearm stress test is necessary to exclude collateral blood flow around stenoses or occlusions of the great arteries. In this case, distal blood pressures are often within a normal range at rest, whereas a drop of pressure in the diseased arteries can be measured after physical exercise. The knowledge of an existing macroangiopathy is important for the differentiation between a primary and a secondary microcirculatory disorder in the meaning of a post-stenotic disturbance of perfusion.
The ED of each patient was assessed by the International Index of Erectile Function (IIEF). 26 Medication with nitrates or doxazosin was interrupted. After 7 days, a baseline capillary microscopy was performed, and repeated 2 h after the intake of 20 mg TAD. The patients received four tablets of TAD at 20 mg each for the use on demand during the next 4 weeks. It was recommended to take one tablet at the weekend. The patient was informed that the clinical effect of TAD can last for 36 h. The efficacy of TAD was reassessed by the IIEF questionnaire 4 weeks later at the last visit. The assessment of the sexual intercourse by the partner was voluntary, giving a mark 1-6 about partner's satisfaction. Nine potential side effects according to the instruction leaflet or the occurrence of angina pectoris, respectively, were evaluated.
Intravital video capillary microscopy
Video capillary microscopy consisting of a reflected light microscope connected in series to a video chain was used for the examination of the capillaries. Erythrocyte velocity measurements in the capillaries were performed by means of an image analysis system 'Cap-Image' (Zeintl Engineering Office, Heidelberg, Germany 27 ). Green light illumination of the skin at a wavelength of approximately 480 nm was used for visualization of the nailfold Microcirculation in erectile dysfunction J-W Park et al capillaries. Owing to the absorption of the green light by the hemoglobin of the erythrocytes, the capillary content appears in dark shades of gray. The vessel wall itself is not visible. So-called plasma gaps are formed at sites without erythrocytes, and can be observed clearly. Figure 1 shows nailfold capillaries of the first row with the arrow indicating a plasma gap.
The present capillary erythrocyte velocity was quantified by frame-to-frame analysis of the video pictures following the motion of the plasma gap. At least 10 measurements per minute were performed in each capillary in order to even out the vasomotion-dependent rhythmic fluctuations (6-10/s) of the red blood cell velocity 28 and expressed as a mean time value (v RBC ). With a normal capillary density (9/mm of the epidermal margin 29 ), approximately 2-4 capillaries could be distinctly observed at a magnification of 1:570. Details of the assessment and error analysis are described elsewhere. 30 To assess the duration of postischemic hyperemia (DpH), which is a measure for vascular reactivity, an arrest of blood supply was performed for 3 min on the upper arm with a pressure cuff at 300 mm Hg. The DpH is defined as the time interval between the release of bloodstream and the restoration of baseline values at rest of erythrocyte velocity in the selected capillaries of the nailfold. Furthermore, the peak velocity of postischemic blood flow was recorded. Determination of the duration of postischemic hyperemia is shown in Figure 2 .
The examinations of the microcirculation were performed under standardized conditions (see Table 1 ). Owing to the marked dependence on temperature of cutaneous microcirculation, adaptation of the patient to room temperature with a skin temperature of at least 27.41C was awaited before the beginning of the measurements. 30 
Control group
To assess the reference ranges of capillary microscopic measurements, 100 apparently healthy volunteers between 45 and 65 years of age were studied. Apparently healthy subjects are defined as follows: lack of any medical history, physical examination without pathological findings, normotensive, normal heart rate and normal laboratory findings (urine analysis, blood sedimentation rate, blood count, plasma concentration of cholesterol and triglyceride). 31 For evaluation of circadian fluctuations of cutaneous microcirculation, eight apparently healthy volunteers were studied at 0800, 1100, 1400 and 1700 hours. The mean age of the patients was 60.377.6 years, the mean marriage years were 31.2714.5 years. The patients suffered from ED since 4.172.6 years. The height of the patients was 17577.1 cm, the body weight 84.778.1 kg.
Twenty patients had an arterial hypertension; diabetes mellitus, eight (IDDM, five; NIDDM, three); current smokers, five; former smokers, eight and the family history of cardiovascular diseases was positive in nine patients.
Eight patients were on treatment with calcium channel blockers, 16 patients with betablockers, 15 with ASA, four with clopidogrel, one with coumadine, 15 with Angiotensin converting enzyme (ACE) inhibitors, six with AT1-blockers, eight with nitrates, five with non-uroselective a-blockers (doxazosin), nine with diuretics and 16 with statines.
The reference range of v RBC , the postischemic erythrocyte peak velocity (v max ) and DpH following 3 min of suprasystolic compression for the cohort of healthy controls is shown in Table 2 . The intraindividual variability of v RBC under resting conditions measured at four time points for 1 day was coefficient of variation ¼ 23.477.8% (P40.05). 30 There were no significant differences between the four samples.
Effect of 20 mg TAD after the first dose
Five out of 25 patients reported no clinical effect of TAD on their ED. In one of these five patients, the laboratory tests revealed a hypogonadism. The patient was referred to the Division of Endocrinology for further treatment.
Among the remaining 20 patients, 10 patients had a successful sexual intercourse once within 48 h after the intake of 20 mg TAD, six patients twice, three patients for three times and one patient had a successful sexual intercourse for four times. The appraisal of the patients concerning the stiffness of their penis during the first sexual intercourse after the intake of TAD was different: five patients rated it as very good, four as good and four as satisfactory. The stiffness of the penis during the second sexual intercourse was reported as follows: Very good, three; good, one and satisfactory two. Two patients had a third (very good, one; satisfactory, one) and one patient a fourth sexual intercourse with sufficient stiffness).
In accordance with the self-assessment of the patients, the partners reported the following: The sexual intercourse was very good, five; good, five; satisfactory, eight; sufficient, one; insufficient, one and unsatisfactory, four. In one case, the partner was not interviewed due to patient's request.
The v RBC increased by 33.3% from 0.3970.25 at rest to 0.5270.23 mm/s 120 min after the intake of 20 mg TAD (P ¼ 0.0028). The v max increased by 14% from 1.3570.65 to 1.5470.61 mm/s 120 min after the intake of 20 mg TAD (P ¼ 0.0281).
The DpH was 96.0766.5 s at rest and 106.7751.8 s 120 min after the intake of 20 mg TAD (P ¼ 0.3611). Figure 3 shows the DpH before and after the intake of 20 mg TAD (patients without clinical effect of TAD depicted with squares at the both ends of the line patients in whom TAD improved the ED depicted with circles at both ends of the line). Patients, who reported no improvement of their ED after the use of TAD also demonstrated a lack of changes of DpH or even a reduction in the duration of DpH. The majority of the patients, who reported at least one successful sexual intercourse due to TAD had a prolongation of DpH. Table 3 shows the IIEF during the last 4 weeks before, or during 4 weeks of the use on demand of Abbreviations: DpH, the duration of the postischemic hyperemia; v max , the maximum postischemic erythrocyte velocity; v RBC , mean capillary red blood cell velocity. 
Effect of TAD on ED
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Discussion
Erectile dysfunction can be attributed to a variety of different causes, such as psychogenic or organic (neurogenic, hormonal, arterial, cavernosal, druginduced) disorders. 32 Therefore, it is often difficult to determine the main cause of ED in individual patients in daily practice. In patients at risk for vascular diseases or with obvious signs of atherosclerosis, respectively, and ED, endothelial dysfunction seems to be the common pathophysiological process. [1] [2] [3] Studies on the flow-mediated vasodilation of the brachial artery, which is a reproducible measure of endothelial health and function, have pointed out impaired vasodilatory capacity in both, patients with ED 10, 11 or CAD. 15, 33, 34 Consequently, striking evidence for a close clinical association of ED and CAD has accumulated, [35] [36] [37] in which ED seems to precede CAD. 38 The use on demand of a PDE5i can produce sustained improvements in erectile function. 20, 21 Additionally, chronic exposure to PDE5i may also ameliorate endothelial function, 39, 40 although some reports can be found which are skeptical about this. 41 A recently published study indicates that chronic therapy with TAD improves endothelial function in patients with increased cardiovascular risk regardless of their degree of ED. 42 Thus, for us it was tempting to hypothesize that in patients with concomitant ED and CAD, the extent of microvascular dysfunction reflects the responsiveness to TAD in terms of erectile function.
In this study, patients presenting both, CAD and ED, showed a significantly reduced v RBC at rest and after 3 min of ischemia compared with age-matched controls. This finding is in accordance with the above-mentioned studies using non-invasive endothelial function test at the brachial artery. 15, 33, 34 At 2 h after the intake of 20 mg TAD, we measured a significant increase of v RBC at rest as well as during 
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J-W Park et al postischemic hyperemia. This is consistent with a study on the use of sildenafil, published recently by our group. 19 In this prospective placebo-controlled, double-blind, randomized crossover trial in 20 patients with CAD, a significant increase of the cutaneous capillary erythrocyte velocity at rest and during postischemic hyperemia was measured after the intake of 50 mg sildenafil.
To assess the erectile function of the patients, an IIEF questionnaire was completed during a 4-week period without the use of TAD, or a 4-week period in which the patients received four tablets of TAD at 20 mg each for the use on demand, respectively. Our study shows a considerable improvement of erectile function in 20 out of 25 patients due to the repeated use of TAD. The results are consistent with those of earlier clinical trials conducted under stringent biometrical demands. [43] [44] [45] Furthermore, a significant correlation between the acute effect of TAD on cutaneous microcirculation and erectile function after 4 weeks of treatment can be demonstrated (r ¼ 0.596; P ¼ 0.0021). The study of Rosano et al. suggests that the improvement of endothelial function can persist even after the medication has been discontinued. 42 Owing to the results of this study and despite of known structural and functional differences of the endothelium from different vascular regions, 46, 47 it seems possible to extrapolate the results of a provocation test in the skin on the penile vasculature if significant proximal stenosis were excluded. On the one hand, the correct interpretation of velocity measurements in the microcirculation is very difficult due to the impact of autoregulation and anatomic variety in different organs. On the other, similar patterns of reaction to provocation are described for different vascular regions. 48 Our results show that a simple non-invasive test using nailfold capillary microscopy could predict the probability of a clinical effect of TAD on ED. Patients with an improved postischemic microvascular reactivity in the acute test will also profit in terms of their erectile function. Otherwise, the test will help to identify patients in which TAD may fail to counteract the dysfunction. Moreover, the following implication may be deduced from this study: In recognition of the penile vascular bed as a sensitive indicator of systemic vascular disease and ED as a sign of early endothelial dysfunction, this test may provide a simple diagnostic tool for physicians to identify men with ED at an early stage in the development of atherosclerosis. It could have an impact on preventive healthcare and may help to prevent adverse vascular events.
Limitations of the study
The sample size of patients, in particular of TAD non-responders included in this study is too small to generalize about the results. This limitation is partly compensated by the prospective design of the study, the consecutive inclusion of all patients presenting with CAD and ED during the study period and the completion of the follow-up in every single patient.
Conclusion
The extent of increase of the postischemic hyperemia in nailfold capillaries due to a single dose of TAD correlates with the improvement of the erectile function assessed by IIEF questionnaire during 4-week TAD on-demand use. Thus, the effect of TAD on the erectile function in patients suffering from both, CAD and ED can be predicted by this simple, non-invasive test. Furthermore, assessment of microvascular dysfunction by nailfold capillary microscopy in men with ED may be a simple tool to identify patients at risk in preventive healthcare.
